Akers Biosciences Completes Clinical Trial for Rapid Diabetic Ketoacidosis Breath Test
THOROFARE, NJ — (Marketwired) — 11/28/16 — Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, has completed a clinical trial for BreathScan® DKA, the first single-use, non-invasive breath test to rapidly screen for diabetic ketoacidosis, a potentially life-threatening complication of diabetes caused by a lack of insulin in the body.The clinical trial was performed at Thomas Jeffers